None
Conditions
Interventions
Etomidate combined with propofol ( Group EP) :EP group: 1%propofol 10ml combined with 2%etomidate 10ml (1:1 volume) 0.15-0.2ml/kg
2. Group C :cyclopofol 0.3-0.4mg/kg
3. The injection of sufentanil 0.1
cyclopol (Group C):1. Group C :cyclopofol 0.3-0.4mg/kg
2. The injection of sufentanil 0.1ug/kg (the first dose of induction should not exceed 5ug) was completed in 10 seconds, and EP mixture or cyclo
Sponsors
Chongqing General Hospital
Eligibility
Sex/Gender
All
Age
65 Years to 90 Years
Inclusion criteria
Inclusion criteria: ? Choose a painless gastroscopy or gastroenteroscopy, and sign an informed consent ?Age =65 years and =90 years, BMI=28kg/m2 ? ASA I~III grade; ? Duration of treatment =1h
Exclusion criteria
Exclusion criteria: ? ASA grade III unstable state after treatment ?Have a history of serious cardiovascular disease (such as heart failure, severe arrhythmia, moderate and severe stenosis or regurgitation of heart valves); Family history of Adams-Stokes syndrome; Patients with unstable angina pectoris, or myocardial infarction within the last 6 months; QTcF interval =450ms(corrected by Fridericia's formula); A history of tachycardia/bradycardia and/or resting electrocardiography requiring medical treatment heart rate 180mmHg and/or diastolic blood pressure > 100mmHg after treatment with antihypertensive drugs; Systolic blood pressure 100 beats/min ? Craniocerebral injury, possible history of intracranial hypertension, brain aneurysm, cerebrovascular accident; A history of mental illness (schizophrenia, mania, psychosis) or long-term psychotropic medications, and cognitive impairment ? Respiratory insufficiency, acute stage of obstructive emphysema, active stage of asthma, upper respiratory tract infection in the past week (accompanied by fever, nasal congestion, sore throat, cough and other symptoms) ? Severe abnormal liver and kidney function (severe abnormal liver function: ALT, bound bilirubin, AST, ALP, one of total bilirubin > 2 times the upper limit of normal; Severe renal dysfunction: Cr clearance 443µmol/L; Patients with severe portal hypertension or increased intra-abdominal pressure ?History of severe diabetic complications (diabetic ketoacidosis, hyperosmolar coma, various infections, large vascular diseases, diabetic nephropathy) ? Severe infection, trauma or major surgery within 4 weeks ? Severe anemia Hb < 70g/L ? Patients at high risk of reflux aspiration; ?Definite history of sleep apnea syndrome and difficult airway; ? Allergy to narcotic drugs ? Participated in another drug clinical study within the past 30 days
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients with successful sedation; | — |
Secondary
| Measure | Time frame |
|---|---|
| incidence of hypotension;incidence of hypoxemia;apnea;duration of sedation onset;recovery time;discharge criteria;injectiong pain;sleep quality;cognitive memory function;nausea. vomiting.myoclnus; | — |
Countries
china
Contacts
Public Contactxuqingqin
chongqing General Hospital
Outcome results
None listed